The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia

Απλή σελίδα τεκμηρίου
dc.contributor.authorNakou, E. S.en
dc.contributor.authorFilippatos, T. D.en
dc.contributor.authorGeorgoula, M.en
dc.contributor.authorKiortsis, D. N.en
dc.contributor.authorTselepis, A. D.en
dc.contributor.authorMikhailidis, D. P.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T16:50:26Z
dc.date.available2015-11-24T16:50:26Z
dc.identifier.issn0300-7995-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/9606
dc.rightsDefault Licence-
dc.subjectbody weighten
dc.subjectezetimibeen
dc.subjectlow density lipoprotein cholesterol (ldl-c)en
dc.subjectobesityen
dc.subjectorlistaten
dc.subjectphospholipase a(2)en
dc.subjectsmall dense ldlen
dc.subjecttriglyceridesen
dc.subjectcardiovascular risk-factorsen
dc.subjectcoronary-heart-diseaseen
dc.subjectlipoprotein-associated phospholipase-a2en
dc.subjectrandomized controlled-trialen
dc.subjectgamma-glutamyl-transferaseen
dc.subjectmetabolic syndromeen
dc.subjectweight-lossen
dc.subjectblood-pressureen
dc.subjectatorvastatinen
dc.subjectparticlesen
dc.titleThe effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemiaen
heal.abstractBackground: Increased concentrations of low density lipoprotein cholesterol (LDL-C), as well as of small dense LDL-C (sdLDL-C), are considered as cardiovascular risk factors. Objective: An assessment of the effects of ezetimibe and orlistat administration, alone or in combination, on LDL-C and sdLDL-C levels (primary endpoint), as well as on anthropometric variables and metabolic parameters (secondary endpoints) in overweight and obese patients [body mass index (BMI) > 28 kg/m(2)] with hypercholesterolaemia [total cholesterol > 200 mg/dL (5.2 mmol/L]. Methods: Eighty six subjects were prescribed a low-fat low-calorie diet and were randomly allocated to receive orlistat 120 mg, 3 times daily (0 group), ezetimibe 10 mg/day (E group) or both (OE group) for 6 months. Results: Significant reductions in LDL-C (-19%, -21 %, -32% in groups O, E and OE, respectively, all p<0.01 vs. baseline) and sdLDL-C levels (-45%, -48%, -76% in groups O, E, OE, respectively, all p<0.01 vs. baseline) were observed. Group OE experienced a significantly greater reduction in LDL-C and sdLDL-C levels compared with groups 0 and E (p< 0.05). Furthermore, significant reductions of BMI, homeostasis model assessment (HOMA) index, serum uric acid, transaminase activities and plasma lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) activity were observed in the O and OE groups. Gamma-glutamyl transpeptidase activity and Lp-PLA(2) activity in overweight and obese hypercholesterolaemic improved significantly more with the combination treatment patients than either drug alone. Furthermore, orlistat, compared with either orlistat or ezetimibe monotherapy. alone or in combination with ezetimibe, Conclusions: Orlistat and ezetimibe combination additionally improved several anthropometric and metabolic had a more favourable effect on LDL-C and sdLDL-C levels variables.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primaryDoi 10.1185/03007990802177150-
heal.identifier.secondary<Go to ISI>://000257952500008-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.1185/03007990802177150-
heal.journalNameCurrent Medical Research and Opinionen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate2008-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ